EPIRUS Biopharmaceuticals, Inc.
EPRSQ
Other OTC0.00
USD
+0.00
- -
ISIN
US29428P1075
CUSIP
29428P107
Return %
Stock
S&P500
1Y
-99.00
26.53
3Y
-99.99
76.60
5Y
-99.87
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jeff Kagy
- Full Time Employees
- 73
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 699 Boylston Street Boston MA United States of America 02116
- IPO Date
- Nov 9, 2005
- Website
- epirusbiopharma.com
- Similar Companies
- Business
- EPIRUS Biopharmaceuticals, Inc. EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is a biopharmaceutical company focused on the development and commercialization of biosimilar monoclonal antibodies targeting immuno-inflammatory diseases and related conditions. The company offers a pipeline of biosimilar product candidates, including BOW015 (infliximab, reference product Remicade), BOW050 (adalimumab, reference product Humira), BOW070 (tocilizumab, reference product Actemra), BOW080 (eculizumab, reference product Soliris), BOW090 (ustekinumab, reference product Stelara), and BOW100 (golimumab, reference product Simponi); these candidates address therapeutic areas such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and rare blood disorders. EPIRUS Biopharmaceuticals conducts research, development, clinical trials, and manufacturing of these cost-effective biologic alternatives, utilizing advanced biotechnology to replicate the structure and function of reference biologics, with operations serving customers worldwide. Founded in 2013 and headquartered in Boston, Massachusetts, the company targets patients and healthcare providers seeking affordable treatments for chronic inflammatory and autoimmune conditions. In recent years, EPIRUS Biopharmaceuticals has pursued strategic growth through partnerships with entities like Livzon Mabpharm Inc. and Polpharma S.A. to accelerate product development and expand market reach; it completed the acquisition of Bioceros Holding B.V. in 2015, adding preclinical candidates to its pipeline and enhancing in-house development capabilities. These initiatives support ongoing global Phase 3 studies and commercialization efforts outside the U.S., amid a shift toward biosimilars amid its current over-the-counter trading status.